Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

With the news of the impending sale of genetic testing company 23andMe, Congress is demanding answers on how customer data will be handled and protected.

Lawmakers have expressed concerns about the privacy of sensitive genetic information and want assurances that clients’ data will not be sold or shared without consent.

Several prominent members of Congress have sent letters to 23andMe’s CEO requesting detailed information about the company’s data privacy policies and procedures.

The sale of 23andMe has raised alarm bells among consumer advocacy groups who fear that personal genetic information could be misused or exploited.

Congress is also seeking clarity on how 23andMe plans to uphold data privacy regulations and prevent any breaches or misuse of customer data.

As genetic testing becomes more prevalent and accessible, safeguarding customer data has become a growing concern for lawmakers and regulators.

23andMe has reassured customers that their data will remain secure and protected, and that the company is committed to upholding strict privacy standards.

However, Congress is calling for more transparency and accountability from the company to ensure that customer data is not compromised in any way.

The sale of 23andMe is expected to be closely monitored by regulators to ensure that data privacy concerns are addressed and customer information is not mishandled.

As the debate over data privacy and protection continues to heat up, Congress is urging companies like 23andMe to prioritize the security and confidentiality of customer data.